Telix Pharmaceuticals Ltd revenue

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Telix Pharmaceuticals Ltd: revenue history, annual

Fiscal year	2023Dec 2023	2024Dec 2024	2025Dec 2025
Revenue	333	517	804
Growth on the year before	—	+55.1%	+55.6%
Gross profit	210	336	426
Gross margin	62.9%	65.1%	53.1%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

Company	Revenue	Growth	3-year growth a year
Telix Pharmaceuticals Ltd	$804m	55.6%	—
TG Therapeutics, Inc.	$800m	76.1%	221.5%
Ascendis Pharma A/s	$814m	106.9%	—
Ionis Pharmaceuticals Inc	$874m	-7.4%	11.5%
Ultragenyx Pharmaceutical Inc.	$717m	17.5%	21.2%
Nurix Therapeutics, Inc.	$702m	738.8%	117.1%

Compare with peers

• TG Therapeutics, Inc. revenue
• Ascendis Pharma A/s revenue
• Ionis Pharmaceuticals Inc revenue
• Ultragenyx Pharmaceutical Inc. revenue
• Nurix Therapeutics, Inc. revenue

Head to head: TGTX vs TLXASND vs TLXIONS vs TLX

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Telix Pharmaceuticals Ltd's SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Telix Pharmaceuticals Ltd.